Login to Your Account



MethylGene, Pharmion Form $272M HDAC Inhibitor Deal

By Karen Pihl-Carey


Wednesday, February 1, 2006
In an arrangement potentially worth $272 million, MethylGene Inc. entered a license and collaboration agreement with Pharmion Corp. focused on histone deacetylase (HDAC) inhibitors. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription